After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Syros Pharmaceuticals Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Syros Pharmaceuticals Inc. is $66.22M. A total of 1.27 million shares were traded on the day, compared to an average of 350.75K shares.
In the most recent transaction, Chee Conley bought 50,000 shares of SYRS for 1.71 per share on Sep 11 ’24. After the transaction, the President & CEO now owns 122,504 company shares. In a previous transaction on Sep 12 ’24, Haas Jason bought 45,344 shares at 1.68 per share. SYRS shares that Chief Financial Officer owns now total 124,552.
Among the insiders who bought shares, Chee Conley acquired of 50,000 shares on Sep 10 ’24 at a per-share price of $1.51. This resulted in the President & CEO holding 72,504 shares of SYRS after the transaction. In another insider transaction, Haas Jason bought 35,363 shares at $1.55 per share on Sep 10 ’24. Company shares held by the Chief Financial Officer now total 59,915.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, SYRS has a high of $8.17 and a low of $1.43.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. SYRS’s latest balance sheet shows that the firm has $130.37M in Cash & Short Term Investments as of fiscal 2021. There were $65.19M in debt and $31.51M in liabilities at the time. Its Book Value Per Share was -$0.24, while its Total Shareholder’s Equity was $85.22M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SYRS is Buy with a score of 5.00.
